Cyltezo

Active Ingredient(s): Adalimumab-adbm
FDA Approved: * August 25, 2017
Pharm Company: * BOEHRINGER INGELHEIM
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Cyltezo Overview

Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.[1][2][3] Use is generally only recommended in people who have not responded to other treatments.[2] It is used by injection under the skin.[1] ...

Read more Cyltezo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Adalimumab

Recent Cyltezo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Adalimumab-adbm
  • Injection: 20mg/0.4ml, 40mg/0.8ml
  • Syringe: 40mg/0.8ml
  • Vial: 40mg/0.8ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Adalimumab-adbm or a similar ingredient: (9 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 November 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA